We are developing GLM101, a novel substrate replacement therapy for PMM2-CDG, a congenital disorder of glycosylation.
2 - 10
π° Series B on 2021-06
November 7
Leadership in clinical operations for rare disease therapeutics at Glycomine.
πΊπΈ United States β Remote
β° Full Time
π΄ Lead
βοΈ Operations